APGE
Income statement / Annual
Last year (2023), Apogee Therapeutics, Inc.'s total revenue was $0.00,
and the percentage change from the previous year is not available.
In 2023, Apogee Therapeutics, Inc.'s net income was -$83.99 M.
See Apogee Therapeutics, Inc.,s key income statements, including revenue, expenses, profit, and income.
Period |
FY-2023
|
FY-2022
|
Period Ended |
12/31/2023 |
12/31/2022 |
Operating Revenue |
$0.00 |
$0.00 |
Cost of Revenue |
$0.00
|
$0.00
|
Gross Profit |
$0.00
|
$0.00
|
Gross Profit Ratio |
0
|
0
|
Research and Development Expenses |
$68.42 M
|
$27.79 M
|
General & Administrative Expenses |
$24.58 M
|
$2.94 M
|
Selling & Marketing Expenses |
$0.00
|
$0.00
|
Selling, General & Administrative Expenses |
$24.58 M
|
$2.94 M
|
Other Expenses |
$0.00
|
$0.00
|
Operating Expenses |
$93.00 M
|
$30.73 M
|
Cost And Expenses |
$93.00 M
|
$30.73 M
|
Interest Income |
$9.02 M
|
$92,000.00
|
Interest Expense |
$0.00
|
$9.15 M
|
Depreciation & Amortization |
$9.02 M
|
$33.52 M
|
EBITDA |
-$83.99 M |
$0.00 |
EBITDA Ratio |
0
|
0
|
Operating Income Ratio |
0
|
0
|
Total Other Income/Expenses Net |
$9.02 M
|
-$9.06 M
|
Income Before Tax |
-$83.99 M
|
-$39.79 M
|
Income Before Tax Ratio |
0
|
0
|
Income Tax Expense |
$0.00
|
-$33,520.00
|
Net Income |
-$83.99 M
|
-$39.79 M
|
Net Income Ratio |
0
|
0
|
EPS |
-3.36 |
-0.79 |
EPS Diluted |
-3.36 |
-0.79 |
Weighted Average Shares Out |
$25.01 M
|
$50.67 M
|
Weighted Average Shares Out Diluted |
$25.01 M
|
$50.67 M
|
Link |
|
|